Updates in the Role of Checkpoint Inhibitor Immunotherapy in Classical Hodgkin’s Lymphoma
Published 2022 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Updates in the Role of Checkpoint Inhibitor Immunotherapy in Classical Hodgkin’s Lymphoma
Authors
Keywords
-
Journal
Cancers
Volume 14, Issue 12, Pages 2936
Publisher
MDPI AG
Online
2022-06-15
DOI
10.3390/cancers14122936
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Response-adapted anti-PD1 based salvage therapy for Hodgkin lymphoma with nivolumab +/- ICE (NICE)
- (2022) Matthew G. Mei et al. BLOOD
- Nivolumab discontinuation and retreatment in patients with relapsed or refractory Hodgkin lymphoma
- (2021) Liudmila V. Fedorova et al. ANNALS OF HEMATOLOGY
- Pembrolizumab versus brentuximab vedotin in relapsed or refractory classical Hodgkin lymphoma (KEYNOTE-204): an interim analysis of a multicentre, randomised, open-label, phase 3 study
- (2021) John Kuruvilla et al. LANCET ONCOLOGY
- Molecular biology of Hodgkin lymphoma
- (2021) Marc A. Weniger et al. LEUKEMIA
- Brentuximab vedotin in combination with nivolumab in relapsed or refractory Hodgkin lymphoma: 3-year study results
- (2021) Ranjana Advani et al. BLOOD
- Improved clinical outcome in a randomized phase II study of anti-PD-1 camrelizumab plus decitabine in relapsed/refractory Hodgkin lymphoma
- (2021) Yang Liu et al. Journal for ImmunoTherapy of Cancer
- 9p24.1 alterations and programmed cell death 1 ligand 1 expression in early stage unfavourable classical Hodgkin lymphoma: an analysis from the German Hodgkin Study Group NIVAHL trial
- (2021) Elena Gerhard‐Hartmann et al. BRITISH JOURNAL OF HAEMATOLOGY
- HL-398: Five-Year Overall Survival from the CheckMate 205 Study of Nivolumab for Relapsed or Refractory (R/R) Classical Hodgkin Lymphoma (cHL)
- (2021) Stephen Ansell et al. Clinical Lymphoma Myeloma & Leukemia
- NIVOLUMAB FOR RELAPSED OR REFRACTORY (R/R) CLASSICAL HODGKIN LYMPHOMA (CHL) AFTER AUTOLOGOUS TRANSPLANTATION: 5‐YEAR OVERALL SURVIVAL FROM THE PHASE 2 CHECKMATE 205 STUDY
- (2021) S. M. Ansell et al. HEMATOLOGICAL ONCOLOGY
- Phase II Trial of Pembrolizumab Plus Gemcitabine, Vinorelbine, and Liposomal Doxorubicin as Second-Line Therapy for Relapsed or Refractory Classical Hodgkin Lymphoma
- (2021) Alison J. Moskowitz et al. JOURNAL OF CLINICAL ONCOLOGY
- Brentuximab vedotin with chemotherapy for stage III or IV classical Hodgkin lymphoma (ECHELON-1): 5-year update of an international, open-label, randomised, phase 3 trial
- (2021) David J Straus et al. Lancet Haematology
- Five-Year Follow-up of Keynote-087: Pembrolizumab Monotherapy in Relapsed/Refractory Classical Hodgkin Lymphoma (R/R cHL)
- (2021) Philippe Armand et al. BLOOD
- Pembrolizumab (PEM) Added to ICE Chemotherapy Results in High Complete Metabolic Response Rates in Relapsed/Refractory Classic Hodgkin Lymphoma (cHL): A Multi-Institutional Phase II Trial
- (2021) Locke J. Bryan et al. BLOOD
- Tislelizumab for Relapsed/Refractory Classical Hodgkin Lymphoma: 3-Year Follow-up and Correlative Biomarker Analysis
- (2021) Yuqin Song et al. CLINICAL CANCER RESEARCH
- Reverted exhaustion phenotype of circulating lymphocytes as immune correlate of anti-PD1 first-line treatment in Hodgkin lymphoma
- (2021) Maria A. Garcia-Marquez et al. LEUKEMIA
- Post-Transplant Nivolumab Plus Unselected Autologous Lymphocytes in Refractory Hodgkin Lymphoma: A Feasible and Promising Salvage Therapy Associated With Expansion and Maturation of NK Cells
- (2021) Fabio Guolo et al. Frontiers in Immunology
- Brentuximab Vedotin in First Refractory/Relapsed Classical Hodgkin Lymphoma Patients Treated By Chemotherapy (ICE) before Autologous Transplantation. Final Analysis of Phase II Study
- (2020) Aspasia Stamatoullas et al. BLOOD
- Brentuximab vedotin with chemotherapy for stage III/IV classical Hodgkin lymphoma: 3-year update of the ECHELON-1 study
- (2020) David J. Straus et al. BLOOD
- Efficacy of anti-PD1 re-treatment in patients with Hodgkin lymphoma who relapsed after anti-PD1 discontinuation
- (2020) Guillaume Manson et al. HAEMATOLOGICA
- Pembrolizumab monotherapy in patients with primary refractory classical hodgkin lymphoma who relapsed after salvage autologous stem cell transplantation and/or brentuximab vedotin therapy: KEYNOTE-087 subgroup analysis
- (2020) Pier Luigi Zinzani et al. LEUKEMIA & LYMPHOMA
- Nivolumab and brentuximab vedotin (BV)-based, response‐adapted treatment in children, adolescents, and young adults (CAYA) with standard-risk relapsed/refractory classical Hodgkin lymphoma (R/R cHL): Primary analysis.
- (2020) Peter D. Cole et al. JOURNAL OF CLINICAL ONCOLOGY
- Efficacy of Nivolumab and AVD in Early-Stage Unfavorable Classic Hodgkin Lymphoma
- (2020) Paul J. Bröckelmann et al. JAMA Oncology
- Low‐dose pembrolizumab and nivolumab were efficacious and safe in relapsed and refractory classical Hodgkin lymphoma: experience in a resource‐constrained setting
- (2020) Thomas S.Y. Chan et al. HEMATOLOGICAL ONCOLOGY
- A peripheral immune signature of responsiveness to PD-1 blockade in patients with classical Hodgkin lymphoma
- (2020) Fathima Zumla Cader et al. NATURE MEDICINE
- Pembrolizumab followed by AVD in untreated early unfavorable and advanced stage classical Hodgkin lymphoma
- (2020) Pamela Blair Allen et al. BLOOD
- Ipilimumab, nivolumab, and brentuximab vedotin combination therapies in patients with relapsed or refractory Hodgkin lymphoma: phase 1 results of an open-label, multicentre, phase 1/2 trial
- (2020) Catherine S Diefenbach et al. Lancet Haematology
- The Confounders of Cancer Immunotherapy: Roles of Lifestyle, Metabolic Disorders and Sociological Factors
- (2020) Ravindra Pramod Deshpande et al. Cancers
- Expression of the Immune Checkpoint Regulators LAG-3 and TIM-3 in Classical Hodgkin Lymphoma
- (2020) Layal El Halabi et al. Clinical Lymphoma Myeloma & Leukemia
- PD-1 Blockade with Pembrolizumab for Classical Hodgkin Lymphoma after Autologous Stem Cell Transplantation
- (2019) Philippe Armand et al. BLOOD
- Addition of Low-Dose Decitabine to Anti–PD-1 Antibody Camrelizumab in Relapsed/Refractory Classical Hodgkin Lymphoma
- (2019) Jing Nie et al. JOURNAL OF CLINICAL ONCOLOGY
- Nivolumab for Newly Diagnosed Advanced-Stage Classic Hodgkin Lymphoma: Safety and Efficacy in the Phase II CheckMate 205 Study
- (2019) Radhakrishnan Ramchandren et al. JOURNAL OF CLINICAL ONCOLOGY
- Pembrolizumab in relapsed or refractory Hodgkin lymphoma: 2-year follow-up of KEYNOTE-087
- (2019) Robert Chen et al. BLOOD
- A single-arm, multicenter, phase 2 study of camrelizumab in relapsed or refractory classical Hodgkin lymphoma
- (2019) Yuqin Song et al. CLINICAL CANCER RESEARCH
- Treatment of relapsed or refractory classical Hodgkin lymphoma with the anti-PD-1, tislelizumab: results of a phase 2, single-arm, multicenter study
- (2019) Yuqin Song et al. LEUKEMIA
- The microenvironmental niche in classic Hodgkin lymphoma is enriched for CTLA-4- positive T-cells that are PD-1-negative
- (2019) Sanjay S. Patel et al. BLOOD
- Brentuximab vedotin plus bendamustine: a highly active first salvage regimen for relapsed or refractory Hodgkin lymphoma
- (2018) Ann S. LaCasce et al. BLOOD
- Major Histocompatibility Complex Class II and Programmed Death Ligand 1 Expression Predict Outcome After Programmed Death 1 Blockade in Classic Hodgkin Lymphoma
- (2018) Margaretha G.M. Roemer et al. JOURNAL OF CLINICAL ONCOLOGY
- Nivolumab for Relapsed/Refractory Classic Hodgkin Lymphoma After Failure of Autologous Hematopoietic Cell Transplantation: Extended Follow-Up of the Multicohort Single-Arm Phase II CheckMate 205 Trial
- (2018) Philippe Armand et al. JOURNAL OF CLINICAL ONCOLOGY
- Brentuximab Vedotin with Chemotherapy for Stage III or IV Hodgkin’s Lymphoma
- (2018) Joseph M. Connors et al. NEW ENGLAND JOURNAL OF MEDICINE
- Five-year PFS from the AETHERA trial of brentuximab vedotin for Hodgkin lymphoma at high risk of progression or relapse
- (2018) Craig H. Moskowitz et al. BLOOD
- Fatal Toxic Effects Associated With Immune Checkpoint Inhibitors
- (2018) Daniel Y. Wang et al. JAMA Oncology
- Long-Term Follow-Up of Contemporary Treatment in Early-Stage Hodgkin Lymphoma: Updated Analyses of the German Hodgkin Study Group HD7, HD8, HD10, and HD11 Trials
- (2017) Stephanie Sasse et al. JOURNAL OF CLINICAL ONCOLOGY
- Phase II Study of the Efficacy and Safety of Pembrolizumab for Relapsed/Refractory Classic Hodgkin Lymphoma
- (2017) Robert Chen et al. JOURNAL OF CLINICAL ONCOLOGY
- Efficacy and tolerability of ABVD and Stanford V for elderly advanced-stage Hodgkin lymphoma (HL): Analysis from the phase III randomized U.S. Intergroup Trial E2496.
- (2017) A. M. Evens et al. JOURNAL OF CLINICAL ONCOLOGY
- Five-year survival and durability results of brentuximab vedotin in patients with relapsed or refractory Hodgkin lymphoma
- (2016) R. Chen et al. BLOOD
- Eight Cycles of ABVD Versus Four Cycles of BEACOPPescalatedPlus Four Cycles of BEACOPPbaselinein Stage III to IV, International Prognostic Score ≥ 3, High-Risk Hodgkin Lymphoma: First Results of the Phase III EORTC 20012 Intergroup Trial
- (2016) Patrice Carde et al. JOURNAL OF CLINICAL ONCOLOGY
- Nivolumab for classical Hodgkin's lymphoma after failure of both autologous stem-cell transplantation and brentuximab vedotin: a multicentre, multicohort, single-arm phase 2 trial
- (2016) Anas Younes et al. LANCET ONCOLOGY
- Adapted Treatment Guided by Interim PET-CT Scan in Advanced Hodgkin’s Lymphoma
- (2016) Peter Johnson et al. NEW ENGLAND JOURNAL OF MEDICINE
- PD-L1 (B7-H1) and PD-1 pathway blockade for cancer therapy: Mechanisms, response biomarkers, and combinations
- (2016) Weiping Zou et al. Science Translational Medicine
- Single or tandem autologous stem-cell transplantation for first-relapsed or refractory Hodgkin lymphoma: 10-year follow-up of the prospective H96 trial by the LYSA/SFGM-TC study group
- (2015) David Sibon et al. HAEMATOLOGICA
- PET-adapted sequential salvage therapy with brentuximab vedotin followed by augmented ifosamide, carboplatin, and etoposide for patients with relapsed and refractory Hodgkin's lymphoma: a non-randomised, open-label, single-centre, phase 2 study
- (2015) Alison J Moskowitz et al. LANCET ONCOLOGY
- Second Cancer Risk Up to 40 Years after Treatment for Hodgkin’s Lymphoma
- (2015) Michael Schaapveld et al. NEW ENGLAND JOURNAL OF MEDICINE
- Single or tandem autologous stem-cell transplantation for first-relapsed or refractory Hodgkin lymphoma: 10-year follow-up of the prospective H96 trial by the LYSA/SFGM-TC study group
- (2015) David Sibon et al. HAEMATOLOGICA
- Omitting Radiotherapy in Early Positron Emission Tomography–Negative Stage I/II Hodgkin Lymphoma Is Associated With an Increased Risk of Early Relapse: Clinical Results of the Preplanned Interim Analysis of the Randomized EORTC/LYSA/FIL H10 Trial
- (2014) John M.M. Raemaekers et al. JOURNAL OF CLINICAL ONCOLOGY
- ABVD in Older Patients With Early-Stage Hodgkin Lymphoma Treated Within the German Hodgkin Study Group HD10 and HD11 Trials
- (2013) Boris Böll et al. JOURNAL OF CLINICAL ONCOLOGY
- Evaluation of treatment outcome in 175 patients with Hodgkin lymphoma aged 60 years or over: the SHIELD study
- (2012) S. J. Proctor et al. BLOOD
- Results of a Pivotal Phase II Study of Brentuximab Vedotin for Patients With Relapsed or Refractory Hodgkin's Lymphoma
- (2012) Anas Younes et al. JOURNAL OF CLINICAL ONCOLOGY
- Randomized Phase III Trial of ABVD Versus Stanford V With or Without Radiation Therapy in Locally Extensive and Advanced-Stage Hodgkin Lymphoma: An Intergroup Study Coordinated by the Eastern Cooperative Oncology Group (E2496)
- (2012) Leo I. Gordon et al. JOURNAL OF CLINICAL ONCOLOGY
- Safety, Activity, and Immune Correlates of Anti–PD-1 Antibody in Cancer
- (2012) Suzanne L. Topalian et al. NEW ENGLAND JOURNAL OF MEDICINE
- Autologous stem cell transplant for early relapsed/refractory Hodgkin lymphoma: results from two transplant centres
- (2011) Stephen D. Smith et al. BRITISH JOURNAL OF HAEMATOLOGY
- Nonmalignant Late Effects and Compromised Functional Status in Survivors of Hematopoietic Cell Transplantation
- (2011) Nandita Khera et al. JOURNAL OF CLINICAL ONCOLOGY
- The classical Hodgkin's lymphoma microenvironment and its role in promoting tumour growth and immune escape
- (2010) Donatella Aldinucci et al. JOURNAL OF PATHOLOGY
- Long-term outcome of autologous stem-cell transplantation in relapsed or refractory Hodgkin's lymphoma
- (2008) B. Sirohi et al. ANNALS OF ONCOLOGY
Find the ideal target journal for your manuscript
Explore over 38,000 international journals covering a vast array of academic fields.
SearchBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started